InvestorsHub Logo
Post# of 252496
Next 10
Followers 832
Posts 119982
Boards Moderated 17
Alias Born 09/05/2002

Re: dav1234 post# 139191

Friday, 10/19/2012 2:45:40 PM

Friday, October 19, 2012 2:45:40 PM

Post# of 252496
CHMP approves Xarelto for treatment of PE and secondary prevention of VTE:

http://www.press.bayer.com/baynews/baynews.nsf/id/Bayers-Xarelto-Rivaroxaban-Recommended-EU-Approval-Treatment-Pulmonary-Embolism-PE-Prevention?OpenDocument&sessionID=1350667966

The PDUFA date for this indication is on or about 11/2/12; JNJ is Bayer's partner in the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.